These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 30361959)

  • 1. Focal Stenting of Complex Femoropopliteal Lesions with the Multi-LOC Multiple Stent Delivery System: 12-Month Results of the Multicenter LOCOMOTIVE Study.
    Sigl M; Beschorner U; Zeller T; Waliszewski M; Langhoff R; Tautenhahn J; Amendt K
    Cardiovasc Intervent Radiol; 2019 Feb; 42(2):169-175. PubMed ID: 30361959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Provisional focal stenting of complex femoropopliteal lesions using the Multi-LOC multiple stent delivery system - 12-month results from the LOCOMOTIVE EXTENDED study.
    Amendt K; Zeller T; Proczka R; Beschorner U; Troisi N; Waliszewski M; Langhoff R; Krankenberg H; Hansch A; Krcmar T; Vidjak V; Nolte-Ernsting C; Hansen A; Sigl M
    Vasa; 2021 Apr; 50(3):209-216. PubMed ID: 33238823
    [No Abstract]   [Full Text] [Related]  

  • 3. PEACE I all-comers registry: patency evaluation after implantation of the 4-French Pulsar-18 self-expanding nitinol stent in femoropopliteal lesions.
    Lichtenberg M; Kolks O; Hailer B; Stahlhoff WF; Tiefenbacher C; Nolte-Ernsting C; Arjumand J; Wittenberg G
    J Endovasc Ther; 2014 Jun; 21(3):373-80. PubMed ID: 24915584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First clinical experience with the Multi-LOC multiple stent delivery system for focal stenting in long femoro-popliteal lesions.
    Amendt K; Beschorner U; Waliszewski M; Sigl M; Langhoff R; Thalwitzer J; Redlich U; Vogel B; Härtel D; Zeller T
    Vasa; 2017 Oct; 46(6):452-461. PubMed ID: 28854856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-level meta-analysis of 999 claudicants undergoing primary femoropopliteal nitinol stent implantation.
    Rocha-Singh KJ; Beckman JA; Ansel G; Lyden SP; Schneider P; Mehta M; Dake M; Mullin CM; Jaff MR;
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1250-1256. PubMed ID: 28303688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of femoropopliteal atherosclerotic lesions using the ranger paclitaxel-coated balloon catheter: 12-month results from an all-comers registry.
    Lichtenberg M; von Bilderling P; Ranft J; Niemöller K; Grell H; Briner L; Saucy F; Rassaf T; Breuckmann F
    J Cardiovasc Surg (Torino); 2018 Feb; 59(1):45-50. PubMed ID: 28980462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
    Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
    J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of the femoropopliteal artery with the bioresorbable REMEDY stent.
    Bontinck J; Goverde P; Schroë H; Hendriks J; Maene L; Vermassen F
    J Vasc Surg; 2016 Nov; 64(5):1311-1319. PubMed ID: 27462002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SUMMIT registry: one-year outcomes after implantation of the EPIC self-expanding nitinol stent in the femoropopliteal segment.
    Werner M; Piorkowski M; Thieme M; Nanning T; Beschorner U; Rastan A; Zeller T; Scheinert D
    J Endovasc Ther; 2013 Dec; 20(6):759-66. PubMed ID: 24325691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-French-compatible endovascular material is safe and effective in the treatment of femoropopliteal occlusive disease: results of the 4-EVER trial.
    Bosiers M; Deloose K; Callaert J; Keirse K; Verbist J; Hendriks J; Lauwers P; D'Archambeau O; Scheinert D; Torsello G; Peeters P
    J Endovasc Ther; 2013 Dec; 20(6):746-56. PubMed ID: 24325689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-Coated Balloons for Complex Femoropopliteal Lesions: 2-Year Results of a Real-World Registry.
    Schmidt A; Piorkowski M; Görner H; Steiner S; Bausback Y; Scheinert S; Banning-Eichenseer U; Staab H; Branzan D; Varcoe RL; Scheinert D
    JACC Cardiovasc Interv; 2016 Apr; 9(7):715-24. PubMed ID: 27056311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, multi-center study of the chocolate balloon in femoropopliteal peripheral artery disease: The Chocolate BAR registry.
    Mustapha JA; Lansky A; Shishehbor M; Miles McClure J; Johnson S; Davis T; Makam P; Crowder W; Konstantino E; Attaran RR;
    Catheter Cardiovasc Interv; 2018 May; 91(6):1144-1148. PubMed ID: 29513389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions.
    Ohki T; Kichikawa K; Yokoi H; Uematsu M; Yamaoka T; Maeda K; Kanaoka Y
    J Vasc Surg; 2017 Jul; 66(1):130-142.e1. PubMed ID: 28400218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
    Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis-Derived Benchmarks of Patency and Target Lesion Revascularization of Percutaneous Balloon Angioplasty from Prospective Clinical Trials of Symptomatic Femoropopliteal In-Stent Restenosis.
    Shammas NW; Jones-Miller S; Lemke J
    J Vasc Interv Radiol; 2016 Aug; 27(8):1195-203. PubMed ID: 27350033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
    Mwipatayi BP; Perera K; Daneshmand A; Daniel R; Wong J; Thomas SD; Burrows SA
    Vascular; 2018 Feb; 26(1):3-11. PubMed ID: 28436316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial.
    Garcia L; Jaff MR; Metzger C; Sedillo G; Pershad A; Zidar F; Patlola R; Wilkins RG; Espinoza A; Iskander A; Khammar GS; Khatib Y; Beasley R; Makam S; Kovach R; Kamat S; Leon LR; Eaves WB; Popma JJ; Mauri L; Donohoe D; Base CC; Rosenfield K;
    Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25969545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
    J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.